Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Payables (2019 - 2025)

Pulmonx (LUNG) has disclosed Payables for 7 consecutive years, with $6.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 39.57% to $6.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.5 million, a 39.57% increase, with the full-year FY2024 number at $7.0 million, up 91.76% from a year prior.
  • Payables was $6.5 million for Q3 2025 at Pulmonx, down from $6.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $18.9 million in Q4 2021 to a low of $1.8 million in Q4 2022.
  • A 5-year average of $8.0 million and a median of $6.5 million in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 90.23% in 2022, then skyrocketed 180.31% in 2024.
  • Pulmonx's Payables stood at $18.9 million in 2021, then tumbled by 90.23% to $1.8 million in 2022, then soared by 97.62% to $3.7 million in 2023, then skyrocketed by 91.76% to $7.0 million in 2024, then fell by 6.83% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Payables are $6.5 million (Q3 2025), $6.7 million (Q2 2025), and $12.1 million (Q1 2025).